Clinical Trial Update: Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating safety and immunotherapeutic activity of cemiplimab (anti-PD-1) in people with HIV on suppressive cART; the study is terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-12-09